Akebia Therapeutics Inc (AKBA) Drops 14.81% on January 05

Equities Staff |

Akebia Therapeutics Inc (AKBA) was one of the Russell 2000's biggest losers for Tuesday January 05 as the stock slid 14.81% to $10.70, a loss of $-1.86 per share. Starting at an opening price of $12.00 a share, the stock traded between $10.66 and $12.13 over the course of the trading day. Volume was 1.12 million shares over 7,371 trades, against an average daily volume of 706,233 shares and a total float of 30.63 million.

The losses send Akebia Therapeutics Inc down to a market cap of $327.76 million. In the last year, Akebia Therapeutics Inc has traded between $14.20 and $5.91, and its 50-day SMA is currently $10.26 and 200-day SMA is $9.39.

Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Akebia Therapeutics Inc is based out of Cambridge, MA and has some 43 employees. Its CEO is John P. Butler.

For a complete fundamental analysis analysis of Akebia Therapeutics Inc , check out Equities.com’s Stock Valuation Analysis report for AKBA. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Spotify

Spotify is a online music service offering providing digital content from a range of record labels and artists. Users can browse through the interface by artist, album, genre, playlist, record…